Cencora, Inc. (COR)

In the past six months, Cencora's stock has shown positive performance. The stock price increased from $280.62 on April 21, 2025, to $292.50 on June 16, 2025, and was $293.92 as of July 18, 2025. Key events impacting the stock include strong financial performance, growth in U.S. Healthcare Solutions, acquisitions, analyst sentiment, insider and congressional trading, dividend declaration, and CEO changes.

Demand for Cencora's products and services generally exhibits minimal seasonality due to the inelastic demand for prescription drugs. While there can be higher-than-expected seasonal demand for certain vaccines, the overall revenue cyclicality for Cencora is low. The company's diversified operations provide a robust and stable revenue stream.

Cencora, Inc., formerly AmerisourceBergen Corporation, is a global healthcare solutions company focused on pharmaceutical sourcing and distribution. Founded in 1947 and headquartered in Conshohocken, Pennsylvania, Cencora plays a crucial role in the global healthcare supply chain by providing drug distribution and related services. The company operates through two main segments: U.S. Healthcare Solutions and International Healthcare Solutions. Its major products and services include pharmaceutical distribution services, specialty pharmaceutical services, global commercialization services, animal health products, consulting and technology solutions, and specialty logistics.

Cencora has a significant global presence, operating in over 50 countries worldwide with local experts and distribution centers. The company has a strong presence in the U.S. and growing international operations, notably expanding its international presence in 2021 by acquiring Alliance Healthcare, a leading drug wholesaler in Europe.

Cencora's brand reputation appears strong, bolstered by its market leadership and extensive distribution network. The company's rebranding from AmerisourceBergen to Cencora in August 2023 was a strategic move to align with its growing global footprint. Events affecting Cencora's reputation include opioid-related litigation, goodwill impairment on PharmaLex, strategic acquisitions, and commitment to philanthropy.

Cencora, Inc. is primarily owned by institutional shareholders. Approximately 95.43% of the company's stock is held by institutional shareholders, 13.98% by Cencora insiders, and 0.00% by retail investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Walgreens Boots Alliance, Inc.